Supernus Pharmaceuticals
Supernus Pharmaceuticals is the current U.S. commercial company behind Myobloc, the principal botulinum toxin type B product in the Botulinum Index graph. Supernus acquired Myobloc as part of the CNS portfolio purchased from US WorldMeds in 2020.
The company connection gives Myobloc a navigable current owner and commercialization node. It does not erase the product’s earlier Solstice Neurosciences and US WorldMeds history, and it should not be interpreted as evidence that type B units are comparable with type A products.
Reference Card
Section titled “Reference Card”| Field | Reference point |
|---|---|
| Company | Supernus Pharmaceuticals, Inc. |
| Base | United States |
| Website | supernus.com |
| Public status | Nasdaq-listed; ticker SUPN |
| Core toxin relationship | Current U.S. commercial portfolio company for Myobloc |
| Main brand node | Myobloc / Neurobloc |
| Product identity | RimabotulinumtoxinB, botulinum toxin type B |
| Manufacturing boundary | Supernus reports reliance on third-party contract manufacturers for commercial products |
Ownership and Commercial History
Section titled “Ownership and Commercial History”Myobloc’s earlier company history includes Solstice Neurosciences and US WorldMeds. In 2020, Supernus agreed to acquire US WorldMeds’ CNS portfolio, including Myobloc, and added the product to its neurology-focused commercial business.
The acquisition is the key relationship event for the current graph. Supernus is the current commercial company node; historical company names remain useful when interpreting older regulatory, corporate, or product materials.
Product Role
Section titled “Product Role”Myobloc is rimabotulinumtoxinB and has a focused U.S. therapeutic role, including cervical dystonia and chronic sialorrhea in adults. Neurobloc was the related European brand name, though European Medicines Agency materials describe that authorization as withdrawn.
Myobloc is not an aesthetic type A peer. Its serotype, intracellular target, potency units, label, and tolerability context require product-specific interpretation.
Manufacturing and Market Limits
Section titled “Manufacturing and Market Limits”Supernus states that it does not currently own or operate facilities for commercial production of its products and relies on contract manufacturing organizations. The company should therefore be described as Myobloc’s current commercial portfolio company, not automatically as the physical manufacturer without a product-specific manufacturing source.